
    
      This study was a multicenter, randomized, double blind, active and placebo controlled,
      parallel group study. Eligible subjects were randomized in a 1:1:1:1 ratio to 1 of the
      following 4 treatment groups:

      A) XP13512 Placebo + Diphenhydramine Placebo (Pbo) B) XP13512 1200 mg/day + Diphenhydramine
      Placebo (1200 mg) C) XP13512 1800 mg/day + Diphenhydramine Placebo (1800 mg) D) XP13512
      Placebo + 50 mg Diphenhydramine (Pbo/DPH)
    
  